lifestyle.marketresearchjournals.com

Author: Cadrenal Therapeutics

Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting

March 31, 2026
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes

March 12, 2026
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion

March 2, 2026
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement

February 24, 2026
Cadrenal’s Pipeline Looks Less Like a Microcap and More Like an Emergency Response System

December 30, 2025
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On

December 29, 2025
Cadrenal’s Quiet Expansion Play Is Starting to Get Loud

December 13, 2025
Cadrenal’s Anticoagulation Platform Is Expanding in a $40 Billion Market

December 13, 2025